← Studies & programmes
Emerging treatmentsFirst study in people — mainly checks safetyOngoing, not accepting participants
P-CD19CD20-ALLO1 donor-cell study in progressive and relapsing MS
Published by MyelinWatch:
P-CD19CD20-ALLO1 donor-cell study in progressive and relapsing MS · The trial tests donor-derived CD19/CD20-targeted cells in relapsing and progressive MS, focusing on safety and cell behaviour.
What is being studied
The trial tests donor-derived CD19/CD20-targeted cells in relapsing and progressive MS, focusing on safety and cell behaviour.
Research stage
First study in people — mainly checks safety
The study continues without taking new participants.
What we know so far
The Phase 1 registry protocol is ongoing without accepting new participants; the cited record has no posted results.
What this means for patients today
Experimental cell therapy, not a proven or currently joinable study in this record; no Greek site is listed.
- Treatment or approach
- P-CD19CD20-ALLO1 donor-cell study in progressive and relapsing MS
- Where the study is running
- Four locations are listed, none in Greece; broader Greek access is not established.
- Published by MyelinWatch
- Last substantive MyelinWatch update